Propofol-associated QTc prolongation.
OBJECTIVE
Propofol is a preferred agent for sedation in patients in the intensive care unit (ICU) due, in part, to its established safety profile. Despite this, recent case reports have suggested a potential for prolongation of the corrected QT interval (QTc) in ICU patients receiving propofol, though limited empirical work has been conducted to evaluate this association. As such, the purpose of this study was to assess the relationship between propofol infusion and QTc prolongation in a historical cohort of ICU patients.


METHODS
A single-center, historical, observational, pre-post cohort analysis of medical records from admitted patients ⩾18 years old with cardiovascular disease was conducted, involving cases who received propofol infusion for ⩾3 hours with sequential electrocardiogram monitoring from 2006 to 2012. A multivariable, generalized linear model regression was employed to assess the primary outcome of on-propofol QTc interval (QTc2), controlling for various demographic and clinical factors.


RESULTS
A total of 96 patients met inclusion criteria, averaging 56.1 ± 14.1 years of age and 86.1 ± 25.0 kg, with 37.5% being female. A mean prolongation in QTc interval of 30.4 ± 55.5 ms (p < 0.001) was observed during the propofol infusion, with 43.8% of cases exhibiting an on-infusion QTc2 of ⩾ 500 ms. Regression analyses suggested that prolongation in on-propofol QTc was independently associated with baseline QTc interval and amiodarone use, while weight as inversely associated with QTc2 (p < 0.05).


CONCLUSIONS
This historical cohort analysis of adult ICU patients receiving propofol suggests that on-infusion QTc prolongation was associated with increasing baseline QTc interval and with amiodarone use. Further research is needed to evaluate the clinical significance and cause-and-effect relationship between potential QTc changes and propofol use in the ICU.
Auburn University Assistant Clinical Professor, Department of Pharmacy Practice Auburn University Harrison School of Pharmacy 650 Clinic Drive, Rm 2100 Mobile, AL 36688.
Michael J
MJ
Scalese
Pharmacist, Department of Pharmacy, Integris Health Edmond, 4801 Integris Parkway, Edmond Oklahoma 73112.
Holly R
HR
Herring
Professor and Chair, Department of Pharmacy: Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, 1110 N Stonewall Ave, Oklahoma City, OK 73117.
R Chris
RC
Rathbun
Associate Professor, Department of Pharmacy: Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, 1110 N Stonewall Ave, Oklahoma City, OK 73117.
Grant H
GH
Skrepnek
Associate Professor, Department of Pharmacy: Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, 1110 N Stonewall Ave, Oklahoma City, OK 73117.
Toni L
TL
Ripley
QTc prolongation; intensive care; propofol; safety